MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,013K
Free Cash flow
-$29,004K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Loss on issuance of liability-cl...
Proceeds from issuance of warran...
Issuance of ascendant liability-...
Others
Negative Cash Flow Breakdown
Net loss
Changes in fair value of financi...
Operating lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-153,067
-5,178
1,585
-7,448
Depreciation and amortization
36
566
678
80
Stock-based compensation
23,838
48
610
1,533
Decrease in the carrying amount of right-of-use-assets
372
363
528
516
Gain on lease termination
0
61
-
-51
Issuance of ascendant liability-classified pre-funded warrants and top-up share obligation
20,119
-
-
-
Amortization of premium/discount on purchased securities
-
-
-30
-182
Loss on issuance of liability-classified warrants
-87,559
-
-
-
Loss (gain) on fixed asset disposal
-
-
-31
-
Changes in fair value of financial instruments
24,487
-
-
-
Amortization of debt issuance costs
0
0
9
10
Accretion of final payment on term loans
0
0
32
33
Accounts receivable
26
-195
5,159
-145
Prepaid expenses and other current assets
233
880
-1,194
764
Deposits
1,047
62
655
12
Foreign withholding tax receivable
0
-
0
1,899
Other payable
-43
314
499
1
Accounts payable
421
-622
1,601
-1,280
Accrued expenses
15,836
-112
-259
352
Research and development contract liability
0
-5,335
-2,481
-1,763
Operating lease liability
-376
-353
-518
-504
Other assets
0
-
-
-
Net cash used in operating activities
-29,004
-10,942
-1,076
-9,024
Purchases of property and equipment
0
121
0
0
Cash received from the sale of property and equipment
-
-
20
20
Purchases of marketable securities
-
-
0
16,288
Redemption of marketable securities
-
-
-7,000
-9,500
Net cash used in investing activities
0
-121
7,020
-6,768
Proceeds from atm offering, net of sales agent commissions and fees
0
306
749
1,001
Proceeds from issuance of warrants and pre-funded warrants, net of transaction costs
27,548
-
10,243
0
Repayment of term loans
0
0
-1,500
-1,000
Proceeds from exercise of stock options
815
-
-
-
Issuance of common stock upon exercise of warrants and pre-funded warrants, net
-
-
0
-
Proceeds from exercise of warrants and pre-funded warrants, net
1,654
-
-
-
Net cash provided by financing activities
30,017
306
9,492
1
Net (decrease) increase in cash, cash equivalents, and restricted cash
1,013
-10,757
15,436
-15,791
Cash, cash equivalents, and restricted cash at beginning of period
16,533
27,290
11,854
22,611
Cash, cash equivalents, and restricted cash at end of period
17,546
16,533
27,290
11,854
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
warrants and pre-funded...
$27,548K
(52.65%↑ Y/Y)
Proceeds from exercise of
warrants and pre-funded...
$1,654K
Proceeds from exercise of
stock options
$815K
Net cash provided by
financing activities
$30,017K
(78.69%↑ Y/Y)
Net (decrease)
increase in cash, cash...
$1,013K
(-79.88%↓ Y/Y)
Canceled cashflow
$29,004K
Loss on issuance of
liability-classified warrants
-$87,559K
Stock-based compensation
$23,838K
(816.49%↑ Y/Y)
Issuance of ascendant
liability-classified pre-funded...
$20,119K
Accrued expenses
$15,836K
(1239.28%↑ Y/Y)
Deposits
$1,047K
(128.60%↑ Y/Y)
Accounts payable
$421K
(-47.64%↓ Y/Y)
Decrease in the carrying
amount of...
$372K
(-74.83%↓ Y/Y)
Depreciation and
amortization
$36K
(-82.00%↓ Y/Y)
Net cash used in
operating activities
-$29,004K
(-150.32%↓ Y/Y)
Canceled cashflow
$149,228K
Net loss
-$153,067K
(-638.06%↓ Y/Y)
Changes in fair value of
financial instruments
$24,487K
Operating lease liability
-$376K
(75.74%↑ Y/Y)
Prepaid expenses and
other current assets
$233K
(-84.92%↓ Y/Y)
Other payable
-$43K
(-122.75%↓ Y/Y)
Accounts receivable
$26K
(106.30%↑ Y/Y)
Buy us a coffee
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)